There’s a new network organizing the incubators, accelerators, and investors fostering innovation in the Pacific Northwest on both sides of the U.S.-Canada border.
Business collaboration across the 49th parallel is having a moment, thanks in no small part to a dramatic... Read more »
With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too.
The FDA will... Read more »
How do you disrupt an industry that markets itself as the embodiment of “forever?”
You bring it back to basics, says Lindsay Reinsmith, co-founder of Ada Diamonds, an online retailer of jewelry with lab-made gemstones in San Francisco. “Science is on... Read more »
On Monday we posted the first part of our look at what should be some of 2018’s most important clinical data, including trials for lung cancer, heart disease, melanoma, Alzheimer’s disease, rare blood disorders, and more. With part two, we’re... Read more »
Genetically modified medicine is here. Two CAR-T therapies, made from a patient’s living T cells, are on the market in the U.S., and many more are in various stages of clinical testing.
As remarkable as they might seem, however, these medicines... Read more »
Author, investor, and AOL co-founder Steve Case today announced a new $150 million venture fund aimed at pumping investment capital into tech companies in so-called flyover states. Contributing to the fund is an impressive group of some of the most successful... Read more »
Many of biotech’s biggest stories in 2017 followed the highly anticipated data from clinical studies. There were monumental successes, like the first-ever approval of a genetically modified living cell therapy, the first FDA application for a gene therapy or a... Read more »
A pair of migraine drugs made a splash in biotech news this week with published data suggesting that they can reduce the frequency of headaches.
These drugs still await an FDA decision, and their impact on patients over the long term... Read more »
From its earliest days, Amazon has built its business on removing the barriers between people and the things they want to buy.
New voice computing technologies and business models unveiled at the company’s annual developer conference in Las Vegas this week... Read more »
If Wednesday’s hearing for Health and Human Services Secretary Nominee Alex Azar is any indication, reining in drug prices and insurance premiums are the policy priorities that will guide Congress’s interaction with the department under a new leader.
For the better... Read more »
Amgen (NASDAQ: AMGN) and Teva Pharmaceutical (NYSE: TEVA) this afternoon are providing the most detailed look yet at two drugs in an emerging class of medicines meant to prevent migraine headaches, rather than just quell their symptoms.
While the... Read more »
The Seattle area’s twin technology behemoths—Microsoft and Amazon—have pursued markedly different real estate strategies over the years, driven in part by the changing character of the region as they’ve grown.
That divergence was underscored Tuesday by Microsoft’s announcement of a major... Read more »
Xconomy convened an outstanding group of innovators in healthcare and artificial intelligence for a half-day conference in Seattle earlier this month. As testament to the excitement around this topic, our event was sold-out with a lengthy waiting list.
Those who made it... Read more »